 |
114 Diseases |  |
361 Trials |
|
361 Trials |  |
7200 News |  |
| «12...8990919293949596979899100101» |
- Enrollment closed, Metastases: POLLY: ER Reactivation Therapy for Breast Cancer (clinicaltrials.gov) - Jan 12, 2015
P2, N=59, Active, not recruiting, Sponsor: Dartmouth-Hitchcock Medical Center
Not yet recruiting --> Active, not recruiting
- ||| Enrollment closed, Trial primary completion date, Combination therapy, Metastases: BOLERO-6: A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer. (clinicaltrials.gov) - Jan 12, 2015
P2, N=297, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2016 --> Jul 2016
- |||||| Kisqali (ribociclib) / Novartis
Enrollment open, Combination therapy, Metastases: MONALEESA-7: Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer (clinicaltrials.gov) - Jan 9, 2015
P3, N=660, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2016 --> Jul 2016 Not yet recruiting --> Recruiting
- ||||| Kisqali (ribociclib) / Novartis
Enrollment change, Trial primary completion date: MONALEESA-2: Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer (clinicaltrials.gov) - Jan 8, 2015
P3, N=650, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting N=500 --> 650 | Trial primary completion date: Jan 2017 --> Aug 2017
- ||||| Kisqali (ribociclib) / Novartis
New P2 trial, Metastases: MONALEESASIA: A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer (clinicaltrials.gov) - Jan 7, 2015
P2, N=112, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- letrozole / Generic mfg.
Trial completion, Trial primary completion date: FRAGRANCE Part A Safety: Study to Find a Genetic Signature of de Novo Resistance to Letrozole (clinicaltrials.gov) - Jan 6, 2015
P2, N=49, Completed, Sponsor: Jules Bordet Institute
N=500 --> 650 | Trial primary completion date: Jan 2017 --> Aug 2017 Recruiting --> Completed | Trial primary completion date: Sep 2014 --> Dec 2014
- Trial primary completion date: HOBOE: A Phase 3 Study of Adjuvant Triptorelin and Tamoxifen, Letrozole, or Letrozole and Zoledronic Acid in Premenopausal Patients With Breast Cancer. (clinicaltrials.gov) - Dec 30, 2014
P3, N=1050, Recruiting, Sponsor: National Cancer Institute, Naples
Recruiting --> Completed | Trial primary completion date: Sep 2014 --> Dec 2014 Trial primary completion date: Jul 2014 --> Jul 2015
- letrozole / Generic mfg., exemestane / Generic mfg.
Enrollment closed, Trial primary completion date, Metastases: Dimethyldiguanide Combined With Aromatase Inhibitor (AI) in Metastatic Breast Cancer (clinicaltrials.gov) - Dec 29, 2014
P2, N=60, Active, not recruiting, Sponsor: Xichun Hu
Trial primary completion date: Jul 2014 --> Jul 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Jun 2015
- taselisib (GDC-0032) / Roche
Trial primary completion date, Combination therapy, Metastases: A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer (clinicaltrials.gov) - Dec 25, 2014
P1/2, N=332, Recruiting, Sponsor: Genentech, Inc.
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Jun 2015 Trial primary completion date: Jul 2017 --> Sep 2019
- ||| metformin / Generic mfg., letrozole / Generic mfg., everolimus / Generic mfg.
Enrollment closed, Metastases: A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma (clinicaltrials.gov) - Dec 19, 2014
P2, N=64, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Jul 2017 --> Sep 2019 Recruiting --> Active, not recruiting
- ||| letrozole / Generic mfg.
Enrollment closed: T-IR- Study to Understand the Effects of Testosterone and Estrogen on the Body's Response to the Hormone Insulin (clinicaltrials.gov) - Dec 19, 2014
P1/2, N=60, Active, not recruiting, Sponsor: University of Washington
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- || letrozole / Generic mfg.
Trial primary completion date, Surgery: Letrozole in Treating Postmenopausal Women With Stage I, II or III Breast Cancer That Can Be Removed by Surgery (clinicaltrials.gov) - Dec 17, 2014
P=N/A, N=200, Recruiting, Sponsor: Vanderbilt-Ingram Cancer Center
Recruiting --> Active, not recruiting Trial primary completion date: Jan 2015 --> Mar 2016
- | everolimus / Generic mfg.
Enrollment open, Combination therapy, Metastases: Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer (clinicaltrials.gov) - Dec 17, 2014
P2, N=46, Recruiting, Sponsor: SCRI Development Innovations, LLC
Trial primary completion date: Jan 2015 --> Mar 2016 Not yet recruiting --> Recruiting
- |||| Gilotrif (afatinib) / Boehringer Ingelheim
Enrollment open, Trial initiation date, Metastases: Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone (clinicaltrials.gov) - Dec 17, 2014
P2, N=150, Recruiting, Sponsor: Translational Research in Oncology
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Apr 2014 --> Jul 2014
- ||||| New P2 trial, Metastases: MIRACLE: Everolimus trIal for Advanced prememopausaL Breast Cancer Patients (clinicaltrials.gov) - Dec 10, 2014
P2, N=200, Not yet recruiting, Sponsor: Chinese Academy of Medical Sciences
- tamoxifen / Generic mfg.
Trial completion: LOGRIBMET: Loss of Grip Strength, BMI, and Adjuvant Endocrine Therapy Breast Cancer (clinicaltrials.gov) - Dec 10, 2014
P=N/A, N=115, Completed, Sponsor: University of Michigan Cancer Center
Not yet recruiting --> Recruiting | Initiation date: Apr 2014 --> Jul 2014 Active, not recruiting --> Completed
- |||| BMS-754807 / BMS
Trial completion, Enrollment change, Trial initiation date: Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors (clinicaltrials.gov) - Dec 9, 2014
P2, N=59, Completed, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=100 --> 59 | Initiation date: Jun 2011 --> Dec 2010
- letrozole / Generic mfg., anastrozole / Generic mfg.
Trial primary completion date: Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer (clinicaltrials.gov) - Dec 6, 2014
P3, N=4160, Terminated, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed | N=100 --> 59 | Initiation date: Jun 2011 --> Dec 2010 Trial primary completion date: Dec 2016 --> Sep 2014
- |||| everolimus / Generic mfg.
Enrollment open: Phase II Study of Everolimus Beyond Progression (clinicaltrials.gov) - Dec 6, 2014
P2, N=70, Recruiting, Sponsor: Emory University
Trial primary completion date: Dec 2016 --> Sep 2014 Not yet recruiting --> Recruiting
- lapatinib / Generic mfg., letrozole / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Neo-All-In: Neoadjuvant Combined Endocrine and HER2 Target Therapy in Postmenopausal Women With ER and Her2 Positive Breast Cancer (clinicaltrials.gov) - Dec 6, 2014
P2, N=25, Completed, Sponsor: Asan Medical Center
Not yet recruiting --> Recruiting Recruiting --> Completed | N=32 --> 25 | Trial primary completion date: Sep 2014 --> Apr 2014
- || letrozole / Generic mfg.
New P3 trial: Comparison Between Letrozole and Laparoscopic Ovarian Drilling in Women With Clomiphene Resistant Polycystic Ovarian Syndrome (PCOS) (clinicaltrials.gov) - Dec 5, 2014
P3, N=210, Recruiting, Sponsor: Cairo University
- | letrozole / Generic mfg., everolimus / Generic mfg.
Enrollment open: Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer (clinicaltrials.gov) - Dec 5, 2014
P2, N=20, Recruiting, Sponsor: Mayo Clinic
Recruiting --> Completed | N=32 --> 25 | Trial primary completion date: Sep 2014 --> Apr 2014 Not yet recruiting --> Recruiting
- || letrozole / Generic mfg., clomifene citrate / Generic mfg.
New P3 trial: Comparison Between Letrozole and Urinary Purified FSH in Women With Clomiphene Citrate Resistant Polycystic Ovarian Syndrome. (clinicaltrials.gov) - Dec 1, 2014
P3, N=210, Recruiting, Sponsor: Cairo University
- || metformin / Generic mfg., letrozole / Generic mfg.
Trial primary completion date: Neoadjuvant Letrozole Plus Metformin vs Letrozole Plus Placebo for ER-positive Postmenopausal Breast Cancer (clinicaltrials.gov) - Nov 25, 2014
P2, N=208, Recruiting, Sponsor: Seoul National University Hospital
Not yet recruiting --> Recruiting Trial primary completion date: Apr 2014 --> Apr 2016
- || Lynparza (olaparib) / Merck (MSD), AstraZeneca
Enrollment change, Metastases: To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer (clinicaltrials.gov) - Nov 25, 2014
P1, N=63, Recruiting, Sponsor: AstraZeneca
Trial primary completion date: Apr 2014 --> Apr 2016 N=84 --> 63
- |||||||||| Ibrance (palbociclib) / Pfizer
New P3 trial, Metastases: A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4] (clinicaltrials.gov) - Nov 23, 2014
P3, N=330, Not yet recruiting, Sponsor: Pfizer
- letrozole / Generic mfg.
Trial primary completion date: Aromatase Inhibitor Host Factors Study (clinicaltrials.gov) - Nov 20, 2014
P=N/A, N=140, Recruiting, Sponsor: Samuel Lunenfeld Research Institute, Mount Sinai Hospital
N=84 --> 63 Trial primary completion date: Sep 2014 --> Sep 2015
- letrozole / Generic mfg.
Trial initiation date: Comparison of 2 Ovarian Stimulation Protocols for Women With Low Ovarian Reserve (clinicaltrials.gov) - Nov 20, 2014
P=N/A, N=200, Not yet recruiting, Sponsor: Sheba Medical Center
Trial primary completion date: Sep 2014 --> Sep 2015 Initiation date: Jun 2014 --> Mar 2015
- ||||| Ibrance (palbociclib) / Pfizer
New P2 trial: PALLET: A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer (clinicaltrials.gov) - Nov 20, 2014
P2, N=306, Not yet recruiting, Sponsor: NSABP Foundation Inc
- letrozole / Generic mfg.
Clinical: Study Evaluating the Timing of Intrauterine Insemination in Relation to Positive Home Ovulation Prediction Kit (clinicaltrials.gov) - Nov 19, 2014
P=N/A, N=250, Recruiting, Sponsor: Midwest Fertility Specialists
- letrozole / Generic mfg.
Clinical: Outcome of Three Controlled Ovarian Hyperstimulation Protocols in Poor Responding Infertility Patients (clinicaltrials.gov) - Nov 18, 2014
P=N/A, N=90, Recruiting, Sponsor: Istanbul University
- | everolimus / Generic mfg.
New P2 trial, Combination therapy, Metastases: Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer (clinicaltrials.gov) - Nov 17, 2014
P2, N=46, Not yet recruiting, Sponsor: SCRI Development Innovations, LLC
- letrozole / Generic mfg., menotropin / Generic mfg.
Enrollment open, Trial primary completion date: Comparison of Treatment Modalities in Poor Responders Undergoing IVF (clinicaltrials.gov) - Nov 14, 2014
P=N/A, N=80, Recruiting, Sponsor: Ercan Bastu
Initiation date: Jun 2014 --> Mar 2015 Not yet recruiting --> Recruiting | Trial primary completion date: Nov 2014 --> Mar 2015
- letrozole / Generic mfg., clomifene citrate / Generic mfg.
New P4 trial: COOL-COS: COmbining Oral Letrozole and Clomiphene for Ovarian Stimulation (clinicaltrials.gov) - Nov 12, 2014
P4, N=40, Not yet recruiting, Sponsor: University of Sao Paulo
- |||||| Verzenio (abemaciclib) / Eli Lilly
Enrollment open: MONARCH 3: A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer (clinicaltrials.gov) - Nov 12, 2014
P3, N=450, Recruiting, Sponsor: Eli Lilly and Company
Not yet recruiting --> Recruiting | Trial primary completion date: Nov 2014 --> Mar 2015 Not yet recruiting --> Recruiting
- Zolinza (vorinostat) / Merck (MSD)
Enrollment closed, Metastases: Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy (clinicaltrials.gov) - Nov 7, 2014
P=N/A, N=8, Active, not recruiting, Sponsor: University of Washington
Not yet recruiting --> Recruiting Completed --> Active, not recruiting
- Zolinza (vorinostat) / Merck (MSD)
Trial primary completion date, Metastases: Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy (clinicaltrials.gov) - Nov 6, 2014
P=N/A, N=15, Active, not recruiting, Sponsor: University of Washington
Completed --> Active, not recruiting Trial primary completion date: Dec 2017 --> May 2014
- | letrozole / Generic mfg., everolimus / Generic mfg.
New P2 trial: Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer (clinicaltrials.gov) - Nov 5, 2014
P2, N=20, Not yet recruiting, Sponsor: Mayo Clinic
- || letrozole / Generic mfg.
Trial primary completion date: Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma (clinicaltrials.gov) - Oct 31, 2014
P2, N=80, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Dec 2017 --> May 2014 Trial primary completion date: Dec 2015 --> Dec 2016
- ||| BMS-754807 / BMS
Trial initiation date: Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors (clinicaltrials.gov) - Oct 31, 2014
P2, N=100, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Dec 2015 --> Dec 2016 Initiation date: Dec 2010 --> Jun 2011
- |||||||||| Kisqali (ribociclib) / Novartis
New P3 trial, Combination therapy, Metastases: MONALEESA-7: Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer (clinicaltrials.gov) - Oct 30, 2014
P3, N=660, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- | taselisib (GDC-0032) / Roche
New P2 trial: A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI) (clinicaltrials.gov) - Oct 24, 2014
P2, N=330, Recruiting, Sponsor: Genentech, Inc.
- imatinib / Generic mfg., letrozole / Generic mfg.
Trial primary completion date: Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast Cancer (clinicaltrials.gov) - Oct 23, 2014
P2, N=45, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Initiation date: Dec 2010 --> Jun 2011 Trial primary completion date: Oct 2015 --> Oct 2016
- | letrozole / Generic mfg., anastrozole / Generic mfg.
Trial termination: Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer (clinicaltrials.gov) - Oct 22, 2014
P3, N=4160, Terminated, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Oct 2015 --> Oct 2016 Active, not recruiting --> Terminated
- ||||| everolimus / Generic mfg.
New P2 trial: Phase II Study of Everolimus Beyond Progression (clinicaltrials.gov) - Oct 22, 2014
P2, N=70, Not yet recruiting, Sponsor: Emory University
- Ibrance (palbociclib) / Pfizer
Phase classification, Combination therapy, Metastases: Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate (clinicaltrials.gov) - Oct 17, 2014
P3, N=0, Available, Sponsor: Pfizer
Active, not recruiting --> Terminated Phase classification: P=N/A --> P3
- ||| Ibrance (palbociclib) / Pfizer
Phase classification, Enrollment change, Metastases: Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer (clinicaltrials.gov) - Oct 17, 2014
P2, N=228, Active, not recruiting, Sponsor: Pfizer
Phase classification: P=N/A --> P3 Phase classification: P1/2 --> P2 | N=177 --> 228
- | Ibrance (palbociclib) / Pfizer
Phase classification, Combination therapy, Metastases: A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer (clinicaltrials.gov) - Oct 10, 2014
P2, N=58, Recruiting, Sponsor: Pfizer
Phase classification: P1/2 --> P2 | N=177 --> 228 Phase classification: P1/2 --> P2
- |||| Herceptin (trastuzumab) / Roche
Enrollment open, Trial primary completion date: HERAKLES: Neoadjuvant Trastuzumab and Letrozole for Postmenopausal Women (clinicaltrials.gov) - Oct 10, 2014
P2, N=132, Recruiting, Sponsor: Gangnam Severance Hospital
Phase classification: P1/2 --> P2 Not yet recruiting --> Recruiting | Trial primary completion date: Jun 2017 --> Oct 2017
- letrozole / Generic mfg.
Trial completion: Letrozole in Preventing Breast Cancer in Healthy Postmenopausal Women at High Risk for Breast Cancer (clinicaltrials.gov) - Oct 4, 2014
P1, N=112, Completed, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting | Trial primary completion date: Jun 2017 --> Oct 2017 Active, not recruiting --> Completed